• Is Cell C sustainable?

    Is the mobile operator another African Bank in the making, asks Gugu Lourie.

  • Alliances that work

    Mutually adding value secures the employer-employee relationship, says Ian Mann.

  • Without prejudice

    We all need to fight the ugly bigotry that’s made news recently, says Mandi Smallhorne.

Loading...
See More

Govt awards R6bn HIV drugs contract

Nov 29 2012 15:12 Reuters
HIV-ARV

(File) (Shutterstock)

Company Data

ASPEN PHARMACARE HOLDINGS LIMITED [JSE:APN]

Last traded 0
Change -9,14
% Change 0
Cumulative volume 1079103
Market cap 197.99bn

Last Updated: 27-01-2015 at 04:28. Prices are delayed by 15 minutes. Source: McGregor BFA

ADCOCK INGRAM HOLDINGS LIMITED [JSE:AIP]

Last traded 0
Change -0,5
% Change 0
Cumulative volume 136365
Market cap 7.57bn

Last Updated: 27-01-2015 at 04:27. Prices are delayed by 15 minutes. Source: McGregor BFA

Related Articles

Aspen boosts profit, Asian unit robust

Aspen: Earning to between rise 18%-24%

Aspen buys GSK Aussie drugs for R2.2bn

Drug firms win R2.5bn tender

Aspen unit to buy drug portfolio from GSK

Aspen prepared to help bridge ARV shortages

 

Johannesburg - South Africa on Thursday awarded a R5.9bn contract to supply life-prolonging HIV medicine to 12 international and domestic firms, to deal with the country's biggest health problem.

Companies that include Aspen Pharmacare Holdings [JSE:APN], Abbott Laboratories and Adcock Ingram Holdings [JSE:AIP] would share the contract, the health department said.

The R5.9bn contract, effective from April next year, aims to increase the number of people on treatment by nearly 50%, to 2.5 million next year.

South Africa has nearly 6 million people infected with HIV - one of the heaviest caseloads in the world. It also has one of largest treatment programmes.

But drug makers are unlikely to rake in big profits from the government award, analysts have said, given the stiff competition in the bidding.

The health department said it saved R2.2bn on the new contract, which it initially expected it would cost R8.1bn.

Aspen Pharmacare, the country's biggest generic drugs maker, was awarded 20% of the contract while its closest domestic rival, Adcock Ingram was given 14%, the health department said.

Other contracts winners included Chicago-based Abbott Laboratories with 8.1%, and domestic firm Cipla Medpro South Africa [JSE:CMP] with 9%.

 

Follow Fin24 on Twitter and Facebook

NEXT ON FIN24X

 

Latest Articles

Invest for Income Read More...
15 Investment Tips for 2015 Read More...
Tax-free saving accounts are coming Read More...
Which generator is right for you? Read More...
 
 

Read Fin24’s Comments Policy

24.com publishes all comments posted on articles provided that they adhere to our Comments Policy. Should you wish to report a comment for editorial review, please do so by clicking the 'Report Comment' button to the right of each comment.

Comment on this story
17 comments
Add your comment
Comment 0 characters remaining
 

Company Snapshot

Money Clinic

Money Clinic
Do you have a question about your finances? We'll get an expert opinion.
Click here...
Loading...